Congress Turns Up the Heat: The Urgent Call for CBD Action
In the labyrinth of American regulatory policy, few issues have lingered in limbo as stubbornly as the oversight of cannabidiol (CBD). The U.S. House of Representatives, through a recent Oversight Committee hearing titled “Restoring Trust in FDA: Rooting Out Illicit Products,” has once again thrust the spotlight on the Food and Drug Administration’s (FDA) sluggish […]
Congress Turns Up the Heat: The Urgent Call for CBD Action Read More »